Market Place
Sourcing Support
Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium
25 Sep 2024 //
GLOBENEWSWIRE
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12 Aug 2024 //
GLOBENEWSWIRE
Erasca Announces Two Trial Collaboration and Supply Agreements for Trametinib
14 Feb 2024 //
GLOBENEWSWIRE
Erasca Announces Publication of Promising Clinical Data Naporafenib
25 Apr 2023 //
GLOBENEWSWIRE
Novartis drug combo shows promise in childhood brain cancer
07 Jun 2022 //
REUTERS
Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist
20 Sep 2020 //
PRESS RELEASE
Novartis` Tafinlar/Mekinist combo improves survival in new Phase 3 data
17 Sep 2020 //
PHARMA FILE
Novartis Tafinlar+ Mekinis demonstrates survival in stage III melanoma
16 Sep 2020 //
GLOBENEWSWIRE
Novartis’ spartalizumab misses primary goal in melanoma study
24 Aug 2020 //
CLINICALTRIALS
Novartis` melanoma combo fails in PhIII
23 Aug 2020 //
PHARMATIMES
Hey, wait up Amgen and Mirati, BI is joining the KRAS crowd as early success
29 Oct 2019 //
ENDPTS
Half of European cancer drug trials ‘biased’, says BMJ
21 Sep 2019 //
PMLIVE
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
Long-term Survival Benefit Shown for Tafinlar + Mekinist in Metastatic Melanoma
04 Jun 2019 //
PR NEWSWIRE
Novartis wins key adjuvant Taf/Mek approval in Europe
29 Aug 2018 //
PM LIVE
Launches in oncology: The elements of success
02 Aug 2018 //
MCKINSEY
FDA approves simultaneous administration of Tafinlar, Mekinist for ATC
09 May 2018 //
IN PHARMATECHNOLOGIST
FDA approves two drugs combined to treat aggressive thyroid cancer
04 May 2018 //
XINHUANET
FDA approval for Novartis` melanoma combo
01 May 2018 //
PHARMA TIMES
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant BRAF V600
30 Apr 2018 //
PR NEWSWIRE
Novartis` combination therapy Tafinlar Mekinist granted FDA Review adjuvant
22 Dec 2017 //
PR NEWSWIRE
Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination
24 Oct 2017 //
REUTERS
Novartis edges Roche in melanoma with adjuvant `breakthrough`
23 Oct 2017 //
FIERCE PHARMA
Novartis: FDA Approves Tafinlar Plus Mekinist For BRAF V600E-mutant NSCLC
23 Jun 2017 //
NASDAQ
Novartis, Bristol-Myers Collaborate for Opdivo Combination
06 Jun 2017 //
NASDAQ
Novartis announces clinical collaboration with BMS
05 Jun 2017 //
GLOBENEWSWIRE
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
01 Jun 2017 //
FIERCE BIOTECH
Array adds Ono as Japanese partner for MEK/BRAF combo
31 May 2017 //
FIERCE BIOTECH
Novartis` targeted meds Tafinlar, Mekinist pick up EU combo approval
05 Apr 2017 //
FIERCE PHARMA
Novartis gets lung cancer OK for Tafinlar/Mekinist combo
03 Apr 2017 //
PMLIVE
Novartis: Tafinlar + Mekinist Gets EU Approval For BRAF V600-positive NSCLC
03 Apr 2017 //
NASDAQ
EMA committee recommends approval of Novartis` Tafinlar + Mekinist
27 Feb 2017 //
PHARMABIZ
J&J gets CHMP backing for broader Darzalex use
27 Feb 2017 //
PMLIVE
Novartis wins CHMP nod for drug combo against some lung cancers
25 Feb 2017 //
REUTERS
Novartis` show superior survival benefit in advanced melanoma in phase III
11 Oct 2016 //
PHARMABIZ
SMC clears three new drugs for NHS Scotland use
14 Sep 2016 //
PHARMATIMES
Novartis receives FDA regular approval for Tafinlar® + Mekinist®
20 Nov 2015 //
MULTIVU
Combination Therapy Continues to Show Survival Benefit Over Vemurafenib
30 Sep 2015 //
FIRST WORD PHARMA
Precision medicine, linked to DNA, still too often misses
29 Aug 2015 //
THE BOSTON GLOBE
Novartis melanoma, anaemia drugs win CHMP favour
27 Jul 2015 //
PHARMA TIMES
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
01 Jun 2015 //
WORLD PHARMA NEWS
Novartis unleashes M&A scouts as GSK deal starts to deliver on margins
23 Apr 2015 //
FIERCE PHARMA
Novartis has fresh data to support newly acquired CLL drug Arzerra
15 Apr 2015 //
FIERCE PHARMA
Gsk and Novartis Asset Swap: A Tale of Two Companies
14 Mar 2015 //
PMLIVE
GSK Deal`s Done. Now, Novartis Has To Deliver On Cancer-Growth Pledge
03 Mar 2015 //
FIERCE PHARMA
EMA Recommended 17 Rare Disease Drugs in 2014
12 Jan 2015 //
EMA
